Tumour cells are able to secrete NKG2D ligands, such as MHC class I chain‐related proteins (MICA and B) or UL‐16 binding proteins (ULBP), expressed on the surface of their exosomes which, upon interaction with NKG2D receptors on NK cells surface, determine their downregulation resulting in a general dysfunction of the immune cell (Ashiru et al., 2010). The gene discussed is KLRK1; the disease is neoplasm.